pancreatic ductal adenocarcinoma

[Nature Reviews Cancer] Scientists review current knowledge of pancreatic ductal adenocarcinoma (PDAC) evolution and heterogeneity, gained from the study of preclinical models and patient biospecimens.

[Scientific Reports] Scientists clarified the role and mechanisms of action of apoptosis-associated speck-like protein containing a caspase recruitment domain in pancreatic ductal adenocarcinoma using clinical evidence and in vitro data.

[Molecules] Scientists investigated whether the autophagy inhibitor chloroquine could potentiate the anticancer effect of pterostilbene in the PDAC cell lines MIA PaCa-2 and BxPC-3, as well as in an orthotopic animal model.

[Journal For Immunotherapy of Cancer] Investigators explored the effects of dipeptidyl peptidase inhibition on the tumor immune landscape using RNAseq, immunohistochemistry, cytokine evaluation and flow cytometry.

[Cell Death Discovery] Researchers formulated a comprehensive single-cell transcriptome atlas and contributed into novel insight of intratumor heterogeneity and molecular mechanism in metastatic pancreatic ductal adenocarcinoma.

[Signal Transduction and Targeted Therapy] Scientists conducted a study by employing a pancreatic ductal adenocarcinoma (PDA)-macrophage co-culture system, an “orthotopic” PDA syngeneic mouse model, and human PDA specimens, together with macrophages derived from GARP knockout mice and multiple analytic tools including whole-genome RNA sequencing,